Abstract
Chemotherapy, the standard of care for advanced colorectal adenocarcinoma (CRC), is increasingly recognized for its ability to activate host immune responses. This study identifies a molecular signaling pathway—the ROS/MondoA/TXNIP/GDF15 axis—that governs this immunomodulatory effect. We demonstrate that chemotherapy-induced stress triggers the transcription factor MondoA to upregulate the tumor suppressor Thioredoxin Interacting Protein (TXNIP), which in turn suppresses Growth/Differentiation Factor 15 (GDF15). Because GDF15 promotes the differentiation of immunosuppressive regulatory T cells (Tregs) via CD48 ligation, the disruption of this axis leads to chemotherapeutic resistance. By analyzing patient-derived tumor organoids (PDTOs) and clinical cohorts, we propose the GDF15/TXNIP ratio as a robust prognostic biomarker and a potential target for overcoming treatment resistance.
Introduction
Colorectal adenocarcinoma (CRC) remains a leading cause of cancer-related mortality worldwide. While traditional chemotherapies like oxaliplatin are primarily valued for their direct cytotoxic effects, their success often depends on "immunogenic cell death"—the ability to transition a "cold" tumor into a "hot" one by stimulating the immune system. However, many patients fail to achieve this transition, leading to treatment resistance. The molecular mechanisms that determine whether chemotherapy successfully remodels the tumor microenvironment have remained largely elusive until now.
The ROS/MondoA/TXNIP/GDF15 Signaling Axis
The researchers identified a specific molecular "switch" that determines the immune outcome of chemotherapy. The process begins with the induction of Reactive Oxygen Species (ROS) by chemotherapeutic agents. Rather than causing indiscriminate damage, these ROS act as signaling molecules that drive the transcription factor MondoA into the nucleus.
Once localized in the nucleus, MondoA activates the expression of TXNIP, a known tumor suppressor. This study reveals a critical new role for TXNIP: it acts as a negative regulator of GDF15. GDF15 is a potent immunosuppressive cytokine that binds to the CD48 receptor on naïve T cells, forcing their differentiation into regulatory T cells (Tregs). These Tregs act as an "immune brake," protecting the tumor from the patient's own immune system. By upregulating TXNIP, chemotherapy effectively releases this brake, allowing for a more robust anti-tumor response.
Methodology and Validation
To validate this pathway, the study employed a multi-layered experimental design:
- Patient-Derived Tumor Organoids (PDTOs): These 3D "mini-tumors" were used to model drug responses in a patient-specific context, allowing for the observation of molecular changes in real-time.
- CRISPR Manipulation: The team used CRISPR-Cas9 knockout and CRISPRa activation to confirm that MondoA and TXNIP are the essential drivers of GDF15 suppression.
- Multi-Omics Profiling: RNA sequencing and mass spectrometry were used to track changes in the secretome (secreted proteins) of cancer cells following chemotherapy.
- Clinical Cohorts: The findings were cross-referenced with data from The Cancer Genome Atlas (TCGA), various Gene Expression Omnibus (GEO) datasets, and local clinical samples, including a specialized cohort of patients with paired biopsies taken before and after oxaliplatin treatment.
Key Results and the GDF15/TXNIP Biomarker
The study's most significant clinical finding is the utility of the GDF15/TXNIP ratio as a predictive tool.
- Prognostic Value: High TXNIP expression combined with low GDF15 levels was independently associated with significantly improved overall survival in CRC patients.
- Predicting Resistance: In public datasets, the GDF15/TXNIP ratio accurately predicted responsiveness to oxaliplatin (p=0.0076). In clinical samples, patients who failed to increase TXNIP expression following chemotherapy were consistently those with advanced, non-responsive disease.
- The Organoid "Sentinel" Metric: The researchers developed a dynamic metric—the "Post-treatment ratio divided by the Pre-treatment ratio." When tested in PDTOs, this metric showed a 28.8-fold difference in significance when comparing aggressive tumors (those with extra-mural invasion) to non-aggressive ones, far outperforming static, single-point measurements.
Discussion and Future Directions
The identification of the TXNIP/GDF15 axis provides a clear molecular explanation for why some tumors remain immunologically "cold" despite aggressive chemotherapy. In resistant or advanced cases, this axis is often dysfunctional or "broken," allowing GDF15 to maintain an immunosuppressive environment dominated by Tregs.
While the requirement for pre- and post-treatment biopsies presents a clinical hurdle, the use of patient-derived organoids as "clinical sentinels" offers a viable path forward. By testing a patient's organoids in the lab, clinicians could potentially predict the success of the ROS/MondoA/TXNIP response before the patient begins treatment. Furthermore, this research opens the door for therapeutic interventions using GDF15 antagonists to restore chemotherapeutic sensitivity in refractory patients. Future studies will investigate whether other stressors, such as radiotherapy, utilize this same MondoA-dependent pathway to influence the tumor microenvironment.
Summary updated